Oragenics and Intrexon to Develop Genetically Modified Probiotics

      Oragenics and Intrexon to Develop Genetically Modified Probiotics

New Exclusive Channel Collaboration focused on Probiotics for the Treatment of
Oral Cavity, Throat, Sinus and Esophagus Diseases

Intrexon Invests $3.9 Million in Oragenics' Common Stock

PR Newswire

TAMPA, Fla. and GERMANTOWN, Md., Oct. 1, 2013

TAMPA, Fla. and GERMANTOWN, Md., Oct. 1, 2013 /PRNewswire/ -- Oragenics, Inc.
(NYSE MKT: OGEN), a leader in the development of novel, effective antibiotics
and oral care probiotics, and Intrexon Corporation (NYSE: XON), a leader in
synthetic biology, today announced the establishment of an Exclusive Channel
Collaboration (ECC) to develop and commercialize genetically modified
probiotics for the treatment of diseases of the oral cavity, throat, sinus and
esophagus. The team is expected to initially focus on therapies for Behcet's
disease and aphthous stomatitis.

The collaborators will utilize their technical and clinical expertise with
genetically modified oral microbes to pursue a novel, short-term therapeutic
agent. The ECC plans to design genetically modified probiotics that will work
orally, administered in, for example, lozenge form rather than through the
digestive system – thereby increasing the probability of effective treatment
outcomes.

It is anticipated that the therapeutic will treat oral lesions associated with
Behcet's, targeting pain management and functional impairment by suppressing
the inflammatory response, reducing frequency of occurrence and avoiding the
onset of new lesions. The same treatment may also be applicable in the more
commonly experienced recurrent aphthuous stomatitis, better known as canker
sores. Both disease states are currently only treated symptomatically and with
limited success.

John N. Bonfiglio, Ph.D., President and Chief of Executive Officer of
Oragenics, was motivated by the continued success of Oragenics' existing ECC
with Intrexon, coupled with the potential market opportunity for a modified
probiotic, to establish an additional collaboration with Intrexon.

"Intrexon's cutting edge technology in gene manipulation enables us to expand
our current expertise in the field of oral probiotics. Working together with
Intrexon, we will capitalize upon the experience gained from our first GM
microbial offering to establish a new modified probiotic that will improve the
lives of currently underserved patients," Bonfiglio said.

Samuel Broder, M.D., Senior Vice President of Intrexon's Health Sector and
former Director of the National Cancer Institute was intrigued by the
possibility of expanding Oragenics' oral probiotics capabilities to encompass
new applications through the collaboration of Intrexon's synthetic biology
expertise.

"Oragenics has an expertise in oral probiotics that lays the foundation for
the development of a genetically modified product, including clinical and
regulatory experience," Dr. Broder said. "Their patented oral probiotic
technology makes the company an ideal collaborator for the treatment of these
unmet clinical needs. We look forward to deepening our already fruitful
collaborative relationship to include this new therapeutic opportunity."

In June 2012, Oragenics and Intrexon entered into an ECC to develop and
commercialize lantibiotics, a novel class of broad-spectrum antibiotics, for
the treatment of infectious diseases. The collaboration recently demonstrated
initial success in producing improved titers of Oragenic's lead compound
MU1140 through a genetically engineered host, progressing toward the goal of
commercial production of lantibiotics.

Through the new ECC, Intrexon will be responsible for technology discovery
efforts, cell-engineering development, and certain aspects of the
manufacturing process. Oragenics will be responsible for conducting
preclinical and clinical development of candidate probiotics, as well as for
other aspects of manufacturing and the commercialization of the product(s).

Under terms of the ECC agreement:

  oOragenics paid Intrexon a technology access fee of $6.0 Million at
    closing, payable in 1,348,000 shares of Oragenics' common stock at a value
    per share of $3.00 and a promissory note in the principal amount of
    $1,956,000. In addition, Oragenics will pay to Intrexon program costs,
    developmental milestone fees and commercial royalties.
  oIntrexon will provide access to its platform technologies and capabilities
    including the UltraVector® platform, DNA and RNA MOD engineering, cell
    system engineering, genome engineering, and protein engineering.

Concurrently with the ECC agreement, Intrexon also purchased 1.3 Million
shares of Oragenics' common stock in a private placement at a price per share
of $3.00 for an aggregate purchase price of $3.9 Million. The net proceeds
will be used for development of key initiatives relating to Organics'
probiotics program that is part of its new exclusive channel collaboration
with Intrexon, and general corporate purposes.

The Oragenics common stock sold to Intrexon in the private placement
transaction has not been registered under the Securities Act of 1933, as
amended (the "Securities Act"), or applicable state securities laws and was
issued and sold in reliance upon the exemption from registration contained in
Section 4(2) of the Securities Act and Regulation D promulgated thereunder.
Accordingly, the securities issued to Intrexon may not be offered or sold in
the United States except pursuant to an effective registration statement or an
applicable exemption from the registration requirements of the Securities Act
and such applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of
an offer to buy Oragenics' securities, nor shall there be any sale of the
securities in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the securities
laws of such jurisdiction.

Griffin Securities acted as advisor on this transaction.

About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader innovel antibiotics
against infectious diseaseand probiotics for oral health for humans and
pets.Oragenics, Inc. has established an exclusive worldwide channel
collaboration for lantibiotics, a novel class of broad spectrum antibiotics,
with Intrexon Corporation Inc., a synthetic biology company.The collaboration
will allow Oragenics access to Intrexon's proprietary technologies with the
idea of accelerating the development of much needed new antibiotics that will
work against resistant strains of bacteria. Oragenics also develops, markets
and sells proprietary probiotics specifically designed to enhance oral health
for humans and pets, under the brand names Evora and ProBiora in over 13
countries worldwide.

For more information about Oragenics, visit www.oragenics.com. Follow
Oragenics on Facebook and Twitter.

About Intrexon Corporation

Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on
collaborating with companies in Health, Food, Energy and the Environment to
create biologically-based products that improve the quality of life and the
health of the planet. Through the company's proprietary UltraVector^®
platform, Intrexon provides its partners with industrial-scale design and
development of complex biological systems. The UltraVector^® platform
delivers unprecedented control over the quality, function, and performance of
living cells. We call our synthetic biology approach and integrated
technologies Better DNA®, and we invite you to discover more at www.dna.com.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of
1995: This release includes forward-looking statements that reflect
management's current views with respect to future events and performance.
These forward-looking statements are based on management's beliefs and
assumptions and information currently available. The words "believe,"
"expect," "anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters identify
forward-looking statements. Investors should be cautious in relying on
forward-looking statements because they are subject to a variety of risks,
uncertainties, and other factors that could cause actual results to differ
materially from those expressed in any such forward-looking statements. These
factors include, but are not limited to those described in the filings of
Intrexon and Oragenics with the U.S. Securities and Exchange Commission. Any
responsibility to update forward-looking statements is expressly disclaimed.



Intrexon Corporate Contact
Peter McLaughlin

Vice President, Corporate Communications

Intrexon Corporation

Tel: 323-842-7779

pmclaughlin@intrexon.com



Oragenics Corporate Contact

John N. Bonfiglio, PhD

Chief Executive Officer

Oragenics, Inc.

4902 Eisenhower Drive, Suite 125

Tampa, Fl 33634

Tel: 813-286-7900 x232

jbonfiglio@oragenics.com


Investor / Media Contacts
Stephanie Carrington / Aaron Estrada

The Ruth Group

Tel: 646-536-7017/7028

scarrington@theruthgroup.com / aestrada@theruthgroup.com







SOURCE Intrexon Corporation

Website: http://www.dna.com
Website: http://www.oragenics.com
 
Press spacebar to pause and continue. Press esc to stop.